The RheumNow Week in Review - 15 December 2017 Save
The RheumNow Week in Review - 15 December 2017-YouTube
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
- NICE and NHS reject the approval of Tocilizumab for use in GCA citing cost concerns https://t.co/TZMmnj91sp https://t.co/aQMFLKVCYo
- Another TNFi biosimilar FDA approved yesterday! This time its Pfizers Ixifi (infliximab-qbtx) becomes the 3rd remicade biosimilar (Inflectra, Renflexis) and the 6th TNFi biosimilar (in addition to Erelzi, Amjevita, Cyltezo) to be FDA approved in 20 mos. https://buff.ly/2C2fWcl
- 240 pts with FUO or inflammation unknown origin (IUO) studied w/ FDG-PET = helpful in Dx of >50% of pts. 190 pts (79.2%) were dx by FDG-PET (Still’s, Lg vessel vasculitis, PMR, IgG4 most common) FDG-PET/CT most helpful with age >50, CRP >30 mg/L & no fever https://buff.ly/2nQcPSK
- Small pilot, controlled, delayed Rx trial of 20 PM/DM pts showed at 3 mos, 50% of Abatacept, but only 11% of control/delayed Rx pts responded to therapy. At 6 mos, with all on ABA, 8/19 responded. ABA has potential and merits further study in PM/DM https://buff.ly/2B4ezgg
- Data presented at American Society of Hematology mtg shows that Abatacept treatment decreases GVHD 32% to 2% in patients receiving hematopoietic stem cell transplants Rx for advanced cancer & other blood disorders https://buff.ly/2kTlmDe
- C4d may be useful in monitoring SLE. C4d PPV 68% for high Dz activty, correlates w/ SLEDAI w/ higer Dz activity & C4d w/ dsDNA 5 fold better ability to predict lupus nephritis. https://t.co/LpUuAaqUWl
- 611 Finnish DMARD NAIVE, Early RA pts (71% RF+) treated with DMARDs, Triple Rx - 68% and 75% achieve DAS28-3 remission at 3 mos and 6 mos respectively. Hence higher response rates with earlier Dx and Rx! https://t.co/iWBs5vhxc7
- Similarities were found between Feltys syndrome and LGL leukemia - in both 40% have somatic STAT3 mutations, expansion of CD8+ T cells, same cytokine profile and STAT3 activation https://buff.ly/2nOLZdB
- Febuxostat Works in Early Gout But Fails to Protect from Xray Damage
- FDA Approves Mepolizumab for Churg-Strauss (EGPA)
- Offspring of RA Women Have Higher Risk of RA and Other Diseases
More ACR Coverage:
ADD THE FIRST COMMENT
Disclosures
Disclosures
The author has received compensation as an advisor or consultant on this subject

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.